On the other hand, excluding several demographic factors, subgroups with positive driver mutations, such as epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK), and PD-L1 tumor proportional score (TPS) < 1% had unfavorable survival after DC, suggesting that those two factors could be tumor-related biomarkers for DC. Here, EGFR is linked to neoplasm.